Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.

Abstract

Adenoid cystic carcinoma (ACC) is the second most common and treatment-resistant salivary gland carcinoma (SGC). Although platinum-based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after platinum therapy remains unclear. We retrospectively analyzed 19 patients with unresectable/metastatic ACC treated with platinum-based therapy between December 2015 and January 2023 at the National Cancer Center Hospital, Japan. Ten patients received eribulin. The median age was 61 years. 84% achieved disease control with the first-line or later platinum-based therapy (median progression-free survival [mPFS]: 7.6 months). Second-line or later eribulin monotherapy yielded a 50% disease control rate, with mPFS of 3.7 months and median overall survival of 41.7 months. The adverse events, predominantly neutropenia, were manageable. Eribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.